» Articles » PMID: 35312711

Common Exacerbation-prone Phenotypes Across Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Abstract

Background And Objectives: Chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD), are complex syndromes with diverse clinical symptoms due to multiple pathophysiological conditions. In this study, using common and shared risk factors for the exacerbation of asthma and COPD, we sought to clarify the exacerbation-prone phenotypes beyond disease labels, and to specifically investigate the role of the IL4RA gene polymorphism, which is related to type 2 inflammation, in these exacerbation-prone phenotypes.

Methods: The study population comprised patients with asthma (n = 117), asthma-COPD overlap (ACO; n = 37) or COPD (n = 48) and a history of exacerbation within the previous year. Cluster analyses were performed using factors associated with both asthma and COPD exacerbation. The association of the IL4RA gene polymorphism rs8832 with each exacerbation-prone phenotype was evaluated by multinomial logistic analyses using non-asthma non-COPD healthy adults as controls (n = 1,529). In addition, the genetic influence of rs8832 was also examined in asthma patients with allergic rhinitis and no history of exacerbation (n = 130).

Results: Two-step cluster analyses identified five clusters that did not necessarily correspond to the diagnostic disease labels. Cluster 1 was characterized by high eosinophil counts, cluster 2 was characterized by smokers with impaired lung function, cluster 3 was characterized by the presence of gastroesophageal reflux, cluster 4 was characterized by non-allergic females, and cluster 5 was characterized by allergic rhinitis and elevated total immunoglobulin E levels. A significant association with rs8832 was observed for cluster 5 (odds ratio, 3.88 (1.34-11.26), p = 0.013) and also for the type 2 exacerbation-prone phenotypes (clusters 1 and 5: odds ratio, 2.73 (1.45-5.15), p = 1.9 × 10-3).

Discussion: Our results indicated that the clinical heterogeneity of disease exacerbation may reflect the presence of common exacerbation-prone endotypes across asthma and COPD, and may support the use of the treatable traits approach for the prevention of exacerbations in patients with chronic inflammatory airway diseases.

Citing Articles

variant may affect the response to type 2 biologics in patients with severe asthma.

Nishi K, Matsumoto H, Sunadome H, Nagasaki T, Oguma T, Tashima N ERJ Open Res. 2025; 11(1.

PMID: 39811553 PMC: 11726575. DOI: 10.1183/23120541.00448-2024.


Common Pathogeneses Underlying Asthma and Chronic Obstructive Pulmonary Disease -Insights from Genetic Studies.

Hizawa N Int J Chron Obstruct Pulmon Dis. 2024; 19:633-642.

PMID: 38464563 PMC: 10922945. DOI: 10.2147/COPD.S441992.


The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly.

Guo M, Yu C, Li Z Contrast Media Mol Imaging. 2022; 2022:8382295.

PMID: 36072633 PMC: 9402387. DOI: 10.1155/2022/8382295.

References
1.
Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K . Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004; 39(9):888-91. DOI: 10.1007/s00535-004-1417-7. View

2.
Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

3.
Shirai T, Mikamo M, Tsuchiya T, Shishido Y, Akita T, Morita S . Real-world effect of gastroesophageal reflux disease on cough-related quality of life and disease status in asthma and COPD. Allergol Int. 2015; 64(1):79-83. DOI: 10.1016/j.alit.2014.08.001. View

4.
Moore W, Meyers D, Wenzel S, Teague W, Li H, Li X . Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2009; 181(4):315-23. PMC: 2822971. DOI: 10.1164/rccm.200906-0896OC. View

5.
Yun J, Lamb A, Chase R, Singh D, Parker M, Saferali A . Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018; 141(6):2037-2047.e10. PMC: 5994197. DOI: 10.1016/j.jaci.2018.04.010. View